Callan Capital LLC Sells 228 Shares of Danaher Co. (NYSE:DHR)

Callan Capital LLC lessened its holdings in Danaher Co. (NYSE:DHR) by 14.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,360 shares of the conglomerate’s stock after selling 228 shares during the period. Callan Capital LLC’s holdings in Danaher were worth $312,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC grew its holdings in shares of Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Danaher by 3.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after purchasing an additional 148,251 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of Danaher by 2.6% during the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after purchasing an additional 116,299 shares during the last quarter. Flossbach Von Storch SE grew its holdings in shares of Danaher by 1.2% during the fourth quarter. Flossbach Von Storch SE now owns 3,710,738 shares of the conglomerate’s stock worth $851,800,000 after purchasing an additional 44,490 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $209.86 on Friday. Danaher Co. has a 52-week low of $196.80 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The business’s 50 day moving average price is $226.71 and its two-hundred day moving average price is $246.96. The firm has a market cap of $151.58 billion, a PE ratio of 39.75, a price-to-earnings-growth ratio of 2.66 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the business earned $2.09 EPS. On average, equities analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. This is a positive change from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio is presently 20.45%.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.10% of the stock is owned by insiders.

Analyst Ratings Changes

DHR has been the topic of several research reports. Raymond James restated a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Citigroup reduced their price target on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Wells Fargo & Company cut their price objective on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Finally, Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research note on Friday, December 13th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.